A Study to Evaluate the Safety and Efficacy of Ombitasvir/Paritaprevir/Ritonavir and Dasabuvir in Adults With Genotype 1b Chronic Hepatitis C Virus (HCV) Infection and Cirrhosis

NCT02219503 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

60

Enrollment

INDUSTRY

Sponsor class

Conditions

Chronic Hepatitis C Infection
Compensated Cirrhosis

Interventions

DRUG: Ombitasvir/Paritaprevir/Ritonavir
DRUG: Dasabuvir

Sponsor

AbbVie